GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyne Therapeutics Inc (NAS:DYN) » Definitions » 3-Year Book Growth Rate

DYN (Dyne Therapeutics) 3-Year Book Growth Rate : -42.00% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Dyne Therapeutics 3-Year Book Growth Rate?

Dyne Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was $6.93.

During the past 12 months, Dyne Therapeutics's average Book Value per Share Growth Rate was 179.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was -42.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 6 years, the highest 3-Year average Book Value per Share Growth Rate of Dyne Therapeutics was -42.00% per year. The lowest was -42.00% per year. And the median was -42.00% per year.

Competitive Comparison of Dyne Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Dyne Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dyne Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyne Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Dyne Therapeutics's 3-Year Book Growth Rate falls into.


Dyne Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Dyne Therapeutics  (NAS:DYN) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Dyne Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Dyne Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Dyne Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyne Therapeutics Inc (NAS:DYN) » Definitions » 3-Year Book Growth Rate
Comparable Companies
FDMT LYEL AVXL ANAB ANTX EWTX TARS ALEC ALLO TSHA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
1560 Trapelo Road, Waltham, MA, USA, 02451
Website
https://www.dyne-tx.com
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
Executives
Dirk Kersten director, 10 percent owner C/O FORBION CAPITAL FUND IV COOPERATIEF, GOOMIER 2-35, NAARDEN P7 14111 DC
Richard William Scalzo officer: See Remarks 25 ALBERTA LANE, HOLLISTON MA 01746
Carlo Incerti director FORBION CAPITAL FUND IV COOPERAITEF U.A., GOOMIER 2-35, NAARDEN P7 1411DC
Oxana Beskrovnaya officer: See Remarks C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Jason P Rhodes director, 10 percent owner C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Susanna Gatti High officer: Chief Operating Officer 75 LORIMER ROAD, BELMONT MA 02141
Wildon Farwell officer: Chief Medical Officer C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET MA 02451
Jonathan Mcneill officer: See Remarks C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Joshua T Brumm director, officer: See Remarks ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Atlas Venture Opportunity Fund I, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Lp 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Romesh Subramanian 10 percent owner, officer: Chief Scientific Officer C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451